Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
Clicks: 374
ID: 270635
1999
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.2
/100
374 views
42 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #3 of 6 articles by views in clinical pharmacokinetics
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Zanamivir is a well tolerated drug. The low level of absorption of the drug after inhaled administration results in low serum concentrations, and therefore there is modest systemic exposure to zanamivir after inhalation. Zanamivir is not metabolised, and the potential for clinically relevant drug-dr …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (44 words).
Try re-searching for a better abstract.
| Reference Key |
lm1999clinicalpharmacokinetics
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Cass LM;Efthymiopoulos C;Bye A;; |
| Journal | clinical pharmacokinetics |
| Year | 1999 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
injections
Administration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
safety
adult
female
male
adolescent
middle aged
Comparative Study
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
reference values
inhalation
antiviral agents / administration & dosage
oral
intravenous
intranasal
guanidines
pyrans
zanamivir
neuraminidase / antagonists & inhibitors
pmid:10429835
doi:10.2165/00003088-199936001-00001
l m cass
c efthymiopoulos
a bye
antiviral agents / pharmacokinetics*
biological availability
sialic acids / administration & dosage
sialic acids / pharmacokinetics*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.